Latest Bionor Pharma ASA (BNRPF) Headlines Bi
Post# of 4
Posted On: 03/09/2014 3:49:22 AM
Latest Bionor Pharma ASA (BNRPF) Headlines
Bionor Pharma's Phase II Vacc-4x Data Published in the Lancet Infectious Diseases
Marketwire - Tue Feb 11, 8:28AM CST
Bionor Pharma ASA (OSE: BIONOR) announces that the results from the randomized, multicenter, double-blinded, placebo-controlled Phase II trial with 135 patients of the Company's lead candidate Vacc-4x will be published in The Lancet Infectious Diseases and available online at www.thelancet.com as of today. An editorial in the same issue, "Shot in the HAART: a vaccine therapy for HIV," adds additional perspective on the value of the trial.
Bionor Pharma Appoints Anker Lundemose as President and Chief Executive Officer
Marketwire - Tue Jan 29, 7:15AM CST
Bionor Pharma ASA (OSLO: BIONOR) today announced that Anker Lundemose, MD, PhD, DMSc (Medical Microbiology), has been appointed as President and CEO of Bionor Pharma ASA from 1 March 2013. Dr. Lundemose is a Danish citizen, and replaces Steen Kroyer, who as of 1 March will take the position as Deputy Chairman of the Board of Directors.
Bionor Pharma's Phase II Vacc-4x Data Published in the Lancet Infectious Diseases
Marketwire - Tue Feb 11, 8:28AM CST
Bionor Pharma ASA (OSE: BIONOR) announces that the results from the randomized, multicenter, double-blinded, placebo-controlled Phase II trial with 135 patients of the Company's lead candidate Vacc-4x will be published in The Lancet Infectious Diseases and available online at www.thelancet.com as of today. An editorial in the same issue, "Shot in the HAART: a vaccine therapy for HIV," adds additional perspective on the value of the trial.
Bionor Pharma Appoints Anker Lundemose as President and Chief Executive Officer
Marketwire - Tue Jan 29, 7:15AM CST
Bionor Pharma ASA (OSLO: BIONOR) today announced that Anker Lundemose, MD, PhD, DMSc (Medical Microbiology), has been appointed as President and CEO of Bionor Pharma ASA from 1 March 2013. Dr. Lundemose is a Danish citizen, and replaces Steen Kroyer, who as of 1 March will take the position as Deputy Chairman of the Board of Directors.
(0)
(0)